S&P 500   3,375.47 (-0.14%)
DOW   27,897.91 (-0.28%)
QQQ   272.26 (+0.15%)
AAPL   458.63 (+1.46%)
MSFT   208.76 (-0.21%)
FB   260.43 (+0.21%)
GOOGL   1,516.87 (+0.64%)
AMZN   3,175.00 (+0.40%)
NVDA   456.88 (-0.16%)
CGC   17.28 (+0.17%)
BABA   253.71 (-0.58%)
TSLA   1,613.91 (+3.80%)
GE   6.61 (-1.64%)
MU   46.10 (-4.91%)
AMD   82.01 (-0.73%)
T   29.89 (-0.96%)
F   7.03 (-1.13%)
ACB   10.27 (+4.80%)
GILD   68.19 (-0.94%)
NFLX   481.93 (+1.36%)
DIS   131.13 (-0.50%)
BAC   26.26 (-1.76%)
BA   175.12 (-0.18%)
S&P 500   3,375.47 (-0.14%)
DOW   27,897.91 (-0.28%)
QQQ   272.26 (+0.15%)
AAPL   458.63 (+1.46%)
MSFT   208.76 (-0.21%)
FB   260.43 (+0.21%)
GOOGL   1,516.87 (+0.64%)
AMZN   3,175.00 (+0.40%)
NVDA   456.88 (-0.16%)
CGC   17.28 (+0.17%)
BABA   253.71 (-0.58%)
TSLA   1,613.91 (+3.80%)
GE   6.61 (-1.64%)
MU   46.10 (-4.91%)
AMD   82.01 (-0.73%)
T   29.89 (-0.96%)
F   7.03 (-1.13%)
ACB   10.27 (+4.80%)
GILD   68.19 (-0.94%)
NFLX   481.93 (+1.36%)
DIS   131.13 (-0.50%)
BAC   26.26 (-1.76%)
BA   175.12 (-0.18%)
S&P 500   3,375.47 (-0.14%)
DOW   27,897.91 (-0.28%)
QQQ   272.26 (+0.15%)
AAPL   458.63 (+1.46%)
MSFT   208.76 (-0.21%)
FB   260.43 (+0.21%)
GOOGL   1,516.87 (+0.64%)
AMZN   3,175.00 (+0.40%)
NVDA   456.88 (-0.16%)
CGC   17.28 (+0.17%)
BABA   253.71 (-0.58%)
TSLA   1,613.91 (+3.80%)
GE   6.61 (-1.64%)
MU   46.10 (-4.91%)
AMD   82.01 (-0.73%)
T   29.89 (-0.96%)
F   7.03 (-1.13%)
ACB   10.27 (+4.80%)
GILD   68.19 (-0.94%)
NFLX   481.93 (+1.36%)
DIS   131.13 (-0.50%)
BAC   26.26 (-1.76%)
BA   175.12 (-0.18%)
S&P 500   3,375.47 (-0.14%)
DOW   27,897.91 (-0.28%)
QQQ   272.26 (+0.15%)
AAPL   458.63 (+1.46%)
MSFT   208.76 (-0.21%)
FB   260.43 (+0.21%)
GOOGL   1,516.87 (+0.64%)
AMZN   3,175.00 (+0.40%)
NVDA   456.88 (-0.16%)
CGC   17.28 (+0.17%)
BABA   253.71 (-0.58%)
TSLA   1,613.91 (+3.80%)
GE   6.61 (-1.64%)
MU   46.10 (-4.91%)
AMD   82.01 (-0.73%)
T   29.89 (-0.96%)
F   7.03 (-1.13%)
ACB   10.27 (+4.80%)
GILD   68.19 (-0.94%)
NFLX   481.93 (+1.36%)
DIS   131.13 (-0.50%)
BAC   26.26 (-1.76%)
BA   175.12 (-0.18%)
Log in

NYSEAMERICAN:YCBDcbdMD Stock Price, Forecast & News

$3.40
+0.04 (+1.19 %)
(As of 08/13/2020 03:31 PM ET)
Add
Compare
Today's Range
$3.36
Now: $3.40▼
$3.58
50-Day Range N/A
52-Week Range
$0.50
Now: $3.40▼
$5.19
Volume32,643 shs
Average Volume1.44 million shs
Market Capitalization$174.54 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
cbdMD, Inc. produces and distributes various cannibidiol (CBD) products in the United States. It operates through three segments: Products, Licensing, and Entertainment. The Products segment produces and markets CBD tinctures, capsules, gummies, bath bombs, vape oils, topical creams, and animal treats and oils under the cdbMD brand. The Licensing segment establishes brands through licensing of select products/categories focusing on health and wellness, and men's lifestyle products. The Entertainment segment produces and markets various entertainment distribution platforms under the EE1 brand. This segment offers recordings, film, TV, Web and live events, and entertainment experiences; and brand management services, including creative development and marketing, brand strategy, and distribution support. cbdMD, Inc. also provides hair care products, including shampoos, conditioners, styling aides, and a patented styling tool through retailers and online outlets. The company was formerly known as Level Brands, Inc. and changed its name to cbdMD, Inc. in May 2019. cbdMD, Inc. was founded in 2015 and is based in Charlotte, North Carolina.
Read More

Beat the Market (BTM) Rank™

Analyst Opinion: 3.0Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank™

1.04 out of 5 stars


Industry, Sector and Symbol

Stock Exchange NYSEAMERICAN
Industry Marketing Services
Sub-IndustryN/A
SectorConsumer Cyclical
Current SymbolNYSEAMERICAN:YCBD
Previous Symbol
CUSIPN/A
CIKN/A
Webwww.cbdmd.com
Phone704-445-5800

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Employees50
Outstanding Shares51,336,000
Market Cap$174.54 million
Next Earnings Date12/16/2020 (Estimated)
OptionableNot Optionable
$3.40
+0.04 (+1.19 %)
(As of 08/13/2020 03:31 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive YCBD News and Ratings via Email

Sign-up to receive the latest news and ratings for YCBD and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











cbdMD (NYSEAMERICAN:YCBD) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of cbdMD?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for cbdMD in the last year. There are currently 2 hold ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for cbdMD.

When is cbdMD's next earnings date?

cbdMD is scheduled to release its next quarterly earnings announcement on Wednesday, December 16th 2020.
View our earnings forecast for cbdMD.

How were cbdMD's earnings last quarter?

cbdMD, Inc. (NYSEAMERICAN:YCBD) announced its earnings results on Wednesday, August, 12th. The company reported ($0.18) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.03) by $0.15.
View cbdMD's earnings history.

What price target have analysts set for YCBD?

2 brokerages have issued 1-year target prices for cbdMD's stock. Their forecasts range from $3.60 to $7.00. On average, they anticipate cbdMD's share price to reach $5.30 in the next twelve months. This suggests a possible upside of 55.9% from the stock's current price.
View analysts' price targets for cbdMD.

Has cbdMD been receiving favorable news coverage?

Press coverage about YCBD stock has been trending extremely negative on Thursday, according to InfoTrie Sentiment. InfoTrie rates the sentiment of news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. cbdMD earned a daily sentiment score of -4.1 on InfoTrie's scale. They also gave media stories about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the company's share price in the immediate future.
View the latest news about cbdMD.

Are investors shorting cbdMD?

cbdMD saw a decline in short interest during the month of June. As of June 30th, there was short interest totaling 1,280,000 shares, a decline of 23.4% from the June 15th total of 1,670,000 shares. Based on an average daily trading volume, of 2,110,000 shares, the short-interest ratio is presently 0.6 days.
View cbdMD's Short Interest.

Who are some of cbdMD's key competitors?

Some companies that are related to cbdMD include oOh!Media (OML), QMS Media (QMS), Wellcom Group (WLL), Tremor International (TRMR), Cello Health (CLL), Taptica International (TAP), Salmat (SLM), IVE Group (IGL), GTN (GTN), Trimantium Growthops (TGO), Inuvo (INUV), Inuvo (INUV), I Synergy Group (IS3), Ebiquity (EBQ) and NAHL Group (NAH).
View all competitors.

What other stocks do shareholders of cbdMD own?

Based on aggregate information from My MarketBeat watchlists, some companies that other cbdMD investors own include Chesapeake Energy (CHKAQ), Chesapeake Energy (CHKAQ), Gran Tierra Energy (GTE), KushCo (KSHB), Cannabics Pharmaceuticals (CNBX), Novan (NOVN), OrganiGram (OGI), Pennsylvania R.E.I.T. (PEI), ADMA Biologics (ADMA) and AEterna Zentaris (AEZS).

What is cbdMD's stock symbol?

cbdMD trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "YCBD."

Who are cbdMD's major shareholders?

cbdMD's stock is owned by a variety of institutional and retail investors. Top institutional investors include AdvisorShares Investments LLC (0.85%), Zeke Capital Advisors LLC (0.45%), Bank of New York Mellon Corp (0.08%), HCR Wealth Advisors (0.04%), Davy Global Fund Management Ltd (0.03%) and Goldman Sachs Group Inc. (0.03%). Company insiders that own cbdMD stock include Bakari T Sellers, Mark S Elliott, Peter J Ghiloni and Raymond Scott Coffman.
View institutional ownership trends for cbdMD.

Which institutional investors are selling cbdMD stock?

YCBD stock was sold by a variety of institutional investors in the last quarter, including Zeke Capital Advisors LLC, Bank of New York Mellon Corp, and Goldman Sachs Group Inc..
View insider buying and selling activity for cbdMD.

Which institutional investors are buying cbdMD stock?

YCBD stock was purchased by a variety of institutional investors in the last quarter, including AdvisorShares Investments LLC, HCR Wealth Advisors, and Davy Global Fund Management Ltd. Company insiders that have bought cbdMD stock in the last two years include Bakari T Sellers, Mark S Elliott, Peter J Ghiloni, and Raymond Scott Coffman.
View insider buying and selling activity for cbdMD.

How do I buy shares of cbdMD?

Shares of YCBD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is cbdMD's stock price today?

One share of YCBD stock can currently be purchased for approximately $3.40.

How big of a company is cbdMD?

cbdMD has a market capitalization of $174.54 million. cbdMD employs 50 workers across the globe.

What is cbdMD's official website?

The official website for cbdMD is www.cbdmd.com.

How can I contact cbdMD?

The company can be reached via phone at 704-445-5800.

This page was last updated on 8/13/2020 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.